For prostate cancer, CARs have been engineered to target antigens overexpressed on prostate tumors compared to normal tissue, including PSMA [104,105], PSCA [106,107] and epithelial cell adhesion molecule (EpCAM) [108]. This evidence concerns the gene EPCAM and prostate carcinoma.